Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From Enemy Territory? NPC Nabs Ex-ICER VP

Executive Summary

Jonathan Campbell is the National Pharmaceutical Council's new chief science officer.

You may also be interested in...



IRA Updates: Lawsuit Filers Push For Fast Decisions, ICER Plans Cost Analyses

Merck & Co. requested a swift summary judgment in the Medicare drug price negotiation case it filed in Washington DC, while the US Chamber of Commerce filed for a preliminary injunction.

Intarcia’s Implantable GLP-1 Gets Unanimous No Vote But Lots Of New Trial Design Advice

US FDA advisory panel feels there could be a place for Intarcia’s exenatide drug-device combo – if the company is willing to put in the work.

As New Tech Emerges For Early Research, FDA Chief Scientist Says Diversity Must Start In Preclinical Development

In a Pink Sheet interview Chief Scientist Bumpus discusses need to move diversity conversation up further in the pipeline. Better ‘organs on a chip’ should help.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel